ClinicalTrials.gg
RecruitingNCT07304518Updated Jan 29, 2026

Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults

A Phase 2 interventional study of PRT-064040 nasal spray and Placebo in Migraine, sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Sichuan Purity Pharmaceutical Technology Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
456
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 80 studies in Migraine Disorders with a site in China — 34 open to participants now, 40 under way, 10 of them phase 3. Migraine Disorders · China.

Planned enrollment
23rd of 61
456 · median 288
Started
2026
with 9 others
Phase 2
5 of 80
2 open now
Primary completion
2026-09
later than 15 of 39 live
Registered
70th of 80
by date

Among the 80 studies in Migraine Disorders with a site in China, this one is the 23rd largest by planned enrollment of the 61 interventional ones that give a count, is one of 10 that started in 2026, is one of 5 in phase 2, reaches primary completion later than 15 of the 39 other live ones, and was the 70th registered.

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

34 of the 80 studies in Migraine Disorders with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Migraine Disorders with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.

03

Conditions studied

  • Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Key Inclusion Criteria:

  1. Male and female participants aged 18-75 years (inclusive);
  2. \< 35 kg/m²;
  3. Participant has at least 1-year history of migraines (with or without aura), consistent with a diagnosis according to the International Classification of Headache Disorder, 3rd Edition;
  4. Age at first migraine onset \< 50 years;
  5. Migraine attacks, on average, lasting about 4-72 hours if untreated or treatment-resistant;
  6. 2-8 attacks of moderate to severe intensity per month within the last 3 months;
  7. Less than 15 days with headache (migraine or non-migraine) per month within the last 3 months;
  8. Participants on prophylactic migraine medication are permitted to remain on therapy provided they have been on a stable dose for at least 3 months prior to screening visit and the dose is not expected to change until the EOT visit;
  9. Patients diagnosed with chronic migraine who, owing to stable preventive therapy, have \< 15 headache days and 2-8 attacks of moderate to severe intensity per month in the 3 months before screening, and who meet all other entry criteria, may be enrolled;
  10. Able to comprehend and complete study questionnaires with electronic patient-reported outcome (e-PRO) application.

Exclusion criteria

Exclusion Criteria:

Key Exclusion Criteria:

  1. Participant with history of migraine with brainstem aura, retinal migraine, or hemiplegic migraine.
  2. Participant with evidence of poorly controlled, unstable, or recently diagnosed cardiovascular or cardiometabolic disease, or prior history thereof, including:

    • Ischemic heart disease, coronary vasospasm, or cerebral ischemia diagnosed within 6 months before screening;
    • Previous stroke, , myocardial infarction, acute coronary syndrome, cardiac surgery, or percutaneous coronary intervention;
    • Abnormal 12-lead at screening;
    • Poorly controlled diabetes mellitus or hypertension;
    • Poorly controlled or severe peripheral vascular disease.
  3. Participant with any nasal structural abnormality, mucosal lesion, or disorder that could interfere with intranasal drug absorption.
  4. Participant with dysgeusia, hypogeusia, or related taste disorders.
  5. Participant with acute or chronic pain syndromes, or any other pain that in the investigator's opinion could confound study assessments.
  6. Participant with history of regular use of ergotamine or triptans ≥ 10 days per month for ≥ 3 months; or regular use of non-narcotic analgesics (e.g., acetaminophen, NSAIDs, gabapentin) ≥ 15 days per month for ≥ 3 months.
  7. abnormal findings in surface antigen, antibody, Treponema pallidum antibody, or antibody tests at screening.
  8. Participant with history of alcohol or drug abuse within 1 year before screening, or positive urine drug screen at screening.
  9. Pregnant or lactating women, or positive pregnancy test at screening.
  10. Participant with known to the product or any of its , or history of significant allergic reactions.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
456 participants (estimated)

Study arms

  • Experimental
    PRT-064040 nasal spray (dose 1)

    Participants administered a single intranasal dose of PRT-064040 nasal spray (dose 1) on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization.

    Drug: PRT-064040 nasal spray

  • Experimental
    PRT-064040 nasal spray (dose 2)

    Participants administered a single intranasal dose of PRT-064040 nasal spray (dose 2) on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization.

    Drug: PRT-064040 nasal spray

  • Experimental
    PRT-064040 nasal spray (dose 3)

    Participants administered a single intranasal dose of PRT-064040 nasal spray (dose 3) on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization.

    Drug: PRT-064040 nasal spray

  • Experimental
    Placebo

    Participants administered a single intranasal dose of placebo on occurrence of migraine that reached moderate or severe intensity within 45 days after randomization.

    Drug: Placebo

Interventions

  • DrugPRT-064040 nasal spray

    A single dose of PRT-064040 nasal spray

  • DrugPlacebo

    A single dose of placebo matched to PRT-064040 nasal spray

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Freedom From Pain at 2 Hours Post-dose

    Time frame: 2 hours post-dose

  2. Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose

    Time frame: 2 hours post-dose

Secondary outcomes

  1. Percentage of Participants With Pain Relief at 15 Minutes Post-dose

    Time frame: 15 minutes post-dose

  2. Percentage of Participants With Pain Relief at 30 Minutes Post-dose

    Time frame: 30 minutes post-dose

  3. Percentage of Participants With Pain Relief at 60 Minutes Post-dose

    Time frame: 60 minutes post-dose

  4. Percentage of Participants With Pain Relief at 2 Hours Post-dose

    Time frame: 2 hours post-dose

  5. Percentage of Participants Who Were Able to Function Normally at 2 Hours Post-dose

    Time frame: 2 hours post-dose

  6. Percentage of Participants With Sustained Pain Relief From 2 Hours to 24 Post-dose

    Time frame: From 2 to 24 hours post-dose

  7. Percentage of Participants With Sustained Pain Relief From 2 Hours to 48 Post-dose

    Time frame: From 2 to 48 hours post-dose

  8. Percentage of Participants Who Were Able to Function Normally at 30 Minutes Post-dose

    Time frame: 30 minutes post-dose

  9. Percentage of Participants Who Were Able to Function Normally at 60 Minutes Post-dose

    Time frame: 60 minutes post-dose

  10. Percentage of Participants With Freedom From Phonophobia at 2 Hours Post-dose

    Time frame: 2 hours post-dose

  11. Percentage of Participants With Freedom From Photophobia at 2 Hours Post-dose

    Time frame: 2 hours post-dose

  12. Percentage of Participants With Freedom From Nausea at 2 Hours Post-dose

    Time frame: 2 hours post-dose

  13. Percentage of Participants With Sustained Pain Freedom From 2 Hours to 24 Post-dose

    Time frame: From 2 to 24 hours post-dose

  14. Percentage of Participants With Sustained Pain Freedom From 2 Hours to 48 Post-dose

    Time frame: From 2 to 48 hours post-dose

  15. Percentage of Participants With Pain Relapse From 2 to 48 Hours Post-dose

    Time frame: From 2 hours to 48 hours post-dose

  16. Percentage of Participants With Rescue Medication Use Within 24 Hours Post-dose

    Time frame: Through 24 hours post-dose

  17. Percentage of Participants Who Were Able to Function Normally at 15 Minutes Post-dose

    Time frame: 15 minutes post-dose

  18. The incidence and severity of adverse events

    Time frame: Through 7(±2) days post-dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Sep 2026, 8 months after the start.

Of 43 industry-sponsored phase 2 interventional studies under Migraine Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 8 months is below that.

Counting every sponsor, half of 73 studies reached it within 15 months; a quarter within 11 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2025
First posted
Dec 26, 2025
StartActual
Jan 26, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Oct 2026
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07304518
Lead sponsor
Sichuan Purity Pharmaceutical Technology Co., Ltd.
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Jan 26, 2026
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Jan 29, 2026

Study contacts

Ke Yao
Contact
ke.yao@btyy.com
86-028-60830544

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion